Fibrates are widely prescribed agonists of transcription factor peroxisome proliferator-activated receptor (PPAR)-α, and are used to treat patients with atherogenic dyslipidemia. These drugs ...

In light of the poor performance and late-stage failures of some drugs targeting PPARs, Gromo says it is important to recognize that all PPAR agonists are unique, and each has different benefits ...

Ipsen has taken rights to PPAR agonist elafibranor as a treatment for primary biliary cholangitis – a chronic, autoimmune disease in which bile ducts in the liver are gradually destroyed causing ...

Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from ...

The decision to abandon seladelpar – a selective peroxisome proliferator-activated receptor (PPAR) delta agonist – came after CymaBay saw “atypical” findings on histology studies from ...

Iqirvo is a first-in-class oral, once-daily peroxisome proliferator-activated receptor (PPAR) agonist. Iqirvo was in-licensed from GENFIT S.A. (NASDAQ:GNFT) in 2021. The expedited approval is ...

The study assesses whether peroxisome proliferator-activated receptor (PPAR) β/δ can regulate InsRβ ... GW501516—a PPARβ/δ agonist—has also been shown to increase InsRβ protein levels ...